Clinical Trial

PET Imaging of Giant Cell and Takayasu Arteritis

Study acronym: PITA
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is often included in the diagnostic work-up of patients with large-vessel vasculitis (LVV), 18F-FDG lacks specificity for inflammatory cells and has limited ability to track therapy response. Moreover, high background 18F-FDG uptake in the brain and myocardium largely precludes imaging temporal arteritis in giant-cell arteritis (GCA) and coronary artery involvement in Takayasu arteritis respectively. These limitations of 18F-FDG for imaging LVV highlight important unmet clinical needs, which might be overcome by using a somatostatin receptor subtype-2 (SST2) PET tracer.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04071691
Lead Sponsor University of Cambridge
Collaborators: Cambridge University Hospitals NHS Foundation Trust, Wellcome Trust, Imperial College London, National Institute for Health Research, United Kingdom
Conditions Giant Cell Arteritis, Takayasu Arteritis
Enrollment 27 participants
Start Date 2019-06-25
Primary Completion 2025-04 (estimated)
Study Completion 2025-04 (estimated)
Updated on ClinicalTrials.gov 2024-07-22